Human Interleukin-29 Recombinant

/, Recombinant Human Cytokines/Human Interleukin-29 Recombinant

Human Interleukin-29 Recombinant

$70.00$4,700.00


accession Q8IU54


Source Optimized DNA sequence encoding Human Interleukin-29(IFN-lambda1) mature chain was expressed in Escherichia Coli.
Molecular weight Native human Interleukin-29, generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 20kDa. Recombinant Interleukin-29(IFN-lambda1)is a monomer protein consisting of 178 amino acid residue subunits,and migrates as an approximately 20kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity >95%, as determined by SDS-PAGE and HPLC
Biological Activity The ED50 is determined in an anti-viral assay using human HepG2 cells infected with EMCV is typically-5 ng/ml.

Protein Sequence MAAAWTVVLV TLVLGLAVAG PVPTSKPTTT GKGCHIGRFK SLSPQELASF KKARDALEES LKLKNWSCSS PVFPGNWDLR LLQVRERPVA LEAELALTLK VLEAAAGPAL EDVLDQPLHT LHHILSQLQA CIQPQPTAGP RPRGRLHHWL HRLQEAPKKE SAGCLEASVT FNLFRLLTRD LKYVADGNLC LRTSTHPEST
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation Recombinant Interleukin-29(IFN-lambda)was lyophilized from a.2 μm filteredmM PB,130mM NaCl solution pH.5.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.


Biological Process Antiviral-defense
Molecular function Cytokine

Methods

V protein expression counteracts the HCV-inhibitory effects of added type I and type III interferons in HFLC.

IL-29
  • Cells were washed three times then refed with HDM containing serial 10-fold dilutions of IFN-β, IL-28A, or IL-29.